ROSEN, LEADING TRIAL ATTORNEYS, Encourages Purchasers of Nike NFTs Issued by RTFKT, Inc. to Inquire About Class Action Investigation
SO WHAT: If you purchased Nike NFTs issued by RTFKT, Inc., you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=36711 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
WHAT IS THIS ABOUT: On December 2, 2024, RTFKT announced on the platform X, its plan to wind down RTFKT operations, injuring investors holding NFTs promoted by Nike.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250269
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Hemostemix's Social Media for Investors and Florida's No-Option Patients
Calgary, Alberta--(Newsfile Corp. - August 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to its investor awareness and social media strategies and programs. The investor outreach campaign includes: Opt-in SMS alerts to keep existing and prospective investors updated on corporate milestones - text 905-580-4170 to opt-in. Targeted opt-in email provides company news, clinical developments, and financing updates: email: sfarooquoi@ Investor platforms and exchanges ( are designed to increase Hemostemix's visibility, providing due diligence level information that retail and institutional audiences seek about our Company's investment opportunities. "Hemostemix has sold forward $1,143,983 in Therapy Convertible Debenture year-to-date," said Thomas Smeenk, CEO. "Frost and Sullivan awarded our Company the Biotechnology Company of the Year Award, Asia, in 2007, for VesCell™ achievements. Now, with 498 treatments, 11 peer reviewed publications including 7 clinical studies of 318 subjects, including Phase II results that validate our patients' testimonials, we are ramping up sales in Florida, investor outreach, and patient engagement simultaneously. VesCell™ won the World Economic Forum Technology Pioneer Award because it regenerates new circulation in the body where that need is signaled. Next week, I'm down to Florida to meet with cardiologists who have done their homework - stay tuned" Smeenk said. Campaign Strategy & Key Highlights - Testimonials and Publications Storytelling: Real patient testimonials about improved cardiac function, reduction of pain and ulcer healing make the science and treatment relatable and compelling. TIME Magazine highlighted VesCell™ recipient, Bob Grinstead, in Take Heart. Watch six time Grammy award winner and VesCell™ recipient Howie Lindeman. Watch Beefsto's Founder, VesCell™ patient #57, Neim Malo. Platform Utilization: Instagram & Facebook: Hemostemix has shared emotionally driven visuals and success narratives to connect directly with patients, caregivers, and broader communities. LinkedIn: Tailored for professionals and investors—Hemostemix is highlighting our clinical milestones, innovations, and corporate positioning. X: Thomas Smeenk, CEO, @HeartRepairGuy, is providing quick, timely updates, and engagement with practitioners and investor audiences. YouTube: Hemostemix posts its longer-form video content including its weekly webinars and VesCell™ patient testimonials: Results Emphasized in Posts: Cardiac Improvements of up to a 47.1% increase in ejection fraction (LVEF%) in dilated cardiomyopathy patients after one treatment, Schubart et al, Stem Cell Research and Therapy. Phase II CLTI: a 99% reduction in ulcerating wounds size, reduced from a mean of 146 mm² to 0.48 mm² by the end of month three (p=0.01), Henderson et al, JBRES1876. Dual Audience Targeting: The campaign bridges two primary goals: Patient Recruitment: Demonstrating hope, safety, and effectiveness of VesCell™ for no-option CLTI, PAD, and heart patients. Liquidity for Investors: Educating investors and shareholders about the HEM's asymmetrical investment upside, using scientifically validated results and milestones achieved. Summary Table Platform Primary Focus Instagram Visual stories of healing and clinical transformation Facebook Patient-centric storytelling and community engagement LinkedIn Corporate, investor, and scientific communications YouTube In-depth video testimonials and informational content X Brief updates, engagement with the medical & investor audience ABOUT HEMOSTEMIX Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@ / PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Company's social media campaign strategy in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Ford Announces $5 Billion Push Toward Electric Vehicles. Here's What Investors Need to Know.
Key Points Ford's $5 billion investment will create a whole new kind of assembly line built from the ground up to make electric vehicles, as well as a whole new kind of superior EV battery. The market being targeted by these improvements, however, may or may not be interested when these vehicles become available. Although a risky bet, Ford stock's low valuation already prices in most (if not all) of this risk. 10 stocks we like better than Ford Motor Company › Switch Auto Insurance and Save Today! Affordable Auto Insurance, Customized for You The Insurance Savings You Expect Great Rates and Award-Winning Service Big news from Ford Motor Company (NYSE: F): The automaker's investing another $5 billion in its electric vehicle business, hoping to drive much-needed sales growth while simultaneously fending off would-be Chinese competitors. The company made the announcement last week. And, kudos. Most long-term shareholders would agree Ford needs to do something -- anything -- to light a fire under its lethargic stock. Ford shares are still priced where they were in 2002, after all, even if decent dividends have been paid for most of the meantime. What's not clear is if this is the best move Ford could make at this time to get shares moving again. Here's what investors need to know about the plan. This investment rethinks its electric vehicles from the ground up The company's already in the EV business, to be clear. It makes a handful of hybrids, although its highest-profile electric vehicles are arguably its all-electric F-150 Lightning and a pretty cool all-electric Mustang called the Mach-E. With the exception of their batteries and electric motors, however, these EVs are still designed and manufactured rather similarly to ordinary combustion-powered automobiles. Ford's $5 billion plan includes a whole new kind of assembly line specifically for electric vehicles. And not just one. This assembly line will be capable of supporting the manufacture of several different kinds of vehicles including a light pickup truck with a targeted starting price point of around $30,000. More than half of the $5 billion investment, however, will be made in the lithium batteries required by all electric vehicles. Ford says its new battery tech can lower the size and cost of EV batteries by around one-third without sacrificing any range per charge, solving one of the EV industry's biggest lingering problems. Ford's existing EV business isn't exactly thrilling ... or profitable As exciting as this decision may be, again, it's not exactly Ford's foray into the electric vehicle market. It's the company's second (and perhaps third) chapter. And its story to date hasn't exactly been thrilling. The aforementioned Mustang Mach-E became available in 2021, while the F-150 Lightning and a new delivery van reached the market in 2022. A few more Ford-made hybrids have been unveiled since then as well. Yet, Ford only sold $3.9 billion worth of electric vehicles last year, down 35% year over year, and only accounting for about 2% of its total top line of $185 billion. Its EV arm also lost a little over $5 billion in 2024, on an operating basis. It's a concern simply because it's difficult to determine if the challenge is a lack of production scale, a lack of demand, or a combination of both. The ambitious goal may be aimed at the wrong market Ford will almost certainly do it right. But, figuring out how to make an affordable and marketable electric vehicle may be of little actual benefit to shareholders. Simply put, Americans as a whole are anything but stoked about battery-powered automobiles. A recent survey performed by the American Automobile Association (which you know as AAA) indicates that only 16% of U.S. adults are likely or very likely to purchase a fully electric automobile. That's down from 2024's figure of 18%, marking three years of declines from 2022's 25%. Conversely, the number of American consumers who are unlikely or very unlikely to purchase an EV has grown from 51% to 63% during that four-year stretch. Ford isn't just a U.S. company, to be clear. It also makes and markets vehicles overseas -- even if largely through partnerships -- where EVs are considerably and increasingly more marketable. For instance, the International Energy Agency believes that 80% of China's new automobile sales will be EVs by 2030, versus only about half of the country's new-car sales now. Ford is mostly an American company though, where it produces roughly two-thirds of its total sales and very nearly all of its profits. And, while the U.S. company's electric vehicle production know-how and battery technology could be utilized elsewhere, it's difficult not to notice the American-ness of its $5 billion plan. The EV production facility in question is located in Louisville, Kentucky, while the new-tech lithium batteries will be manufactured in Marshall, Michigan. Let's also not look past the fact that the one vehicle Ford has touted that will be made by this new assembly line is a low-cost pickup truck, which, of course, is wildly more popular here than anywhere else in the world. This is (almost) an all-in bet on the company's future Given the American-centric nature of Ford's big investment in EVs, largely aimed at a market that isn't exactly in love with battery-powered vehicles, the concerns being voiced are understandable. Although the cost doesn't quite present the existential crisis that some analysts are hinting at, it is a sizable bet for any struggling company that only clears about $5 billion in net income per year and is sitting on more than $100 billion in long-term liabilities. If Americans don't come around on electric vehicles by the time they start coming off of Ford's new assembly line in 2027, the company's current challenges will only worsen. As such, there's no room for any error here, including errors in judgment as to the future marketability of EVs in the United States. That's why any interested investor will want to think very carefully before plowing into a new stake in this carmaker. Still, with Ford shares priced at only about 8 times next year's expected per-share earnings of $1.40 and a trailing dividend yield of just over 5%, it seems most (if not all) of this risk is already priced in. It wouldn't be unreasonable to find a little bit of room in your portfolio for Ford stock at this time. You just might want to contain your risk by keeping any position in this name smaller than you might normally take on. Should you invest $1,000 in Ford Motor Company right now? Before you buy stock in Ford Motor Company, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Ford Motor Company wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 James Brumley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Ford Announces $5 Billion Push Toward Electric Vehicles. Here's What Investors Need to Know. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Elon Musk says Tesla's new six-seat Model Y might never come to the US
Tesla just launched an extended, six-seat version of the Model Y in China. CEO Elon Musk said it might never go into production in the US due to the rise of self-driving cars. Tesla is battling fierce EV competition in China, but is going all in on robotaxis in the US. Tesla's new six-seat Model Y is creating plenty of buzz in China — but don't expect to see it in the US anytime soon. Switch Auto Insurance and Save Today! Great Rates and Award-Winning Service Affordable Auto Insurance, Customized for You The Insurance Savings You Expect CEO Elon Musk said on Wednesday that the Model Y L, an extended version of Tesla's most popular vehicle with three rows of seats, might never arrive on American shores. "This variant of the Model Y doesn't start production in the US until the end of next year. Might not ever, given the advent of self-driving in America," wrote Musk in a post on X. The Model Y L, which adds new features including a rear row of foldable seats and powered armrests, went on sale for $47,200 in China on Tuesday. Its launch comes as Tesla battles fierce competition from local EV players like BYD, Xiaomi, and Xpeng. Electric vehicle adoption in China is far higher than in the US, and Chinese companies have rapidly taken market share with a wave of affordable electric models packed with high-tech features, including autonomous driving and voice controls. The Model Y, China's best-selling SUV, is facing a number of new challengers. In June, smartphone giant-turned EV maker Xiaomi launched the YU7, an electric SUV priced just below the Model Y. Xiaomi says the YU7 received nearly 300,000 preorders in an hour after it launched. EV startups Xpeng and Nio have also unveiled their own Model Y rivals in recent weeks. In the US, where Chinese EVs are not available due to high tariffs, Tesla has increasingly focused on its robotaxi and ride-hailing services. The company launched its first robotaxi service, which is currently invite-only, in Austin in June. Musk has predicted that driverless vehicles will become the norm over the next decade, and told investors last October that building a regular non-robotaxi model would be "pointless." The last new product Tesla launched in the US was the Cybertruck, which has been a sales flop since it made its debut in 2023. The company has said it is planning to release an affordable model, which Musk has described as "just a Model Y," in the fourth quarter of 2025. Tesla did not immediately respond to a request for comment, sent outside normal working hours. Read the original article on Business Insider Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
